Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CONMED Corporation stock logo
CNMD
CONMED
$52.01
-0.6%
$55.18
$46.00
$78.19
$1.61B1.24445,505 shs1.21 million shs
Enovis Corporation stock logo
ENOV
Enovis
$31.78
-1.5%
$33.06
$28.83
$49.83
$1.82B1.72883,656 shs9.30 million shs
NovoCure Limited stock logo
NVCR
NovoCure
$18.00
+5.3%
$17.66
$14.17
$34.13
$2.01B0.741.14 million shs3.33 million shs
Westaim Corp. stock logo
WEDXF
Westaim
$22.59
+0.2%
$23.00
$16.62
$25.98
$758.12M0.242,963 shs500 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CONMED Corporation stock logo
CNMD
CONMED
0.00%-0.36%-8.38%-14.18%-24.97%
Enovis Corporation stock logo
ENOV
Enovis
0.00%+5.47%+1.47%-16.92%-29.69%
NovoCure Limited stock logo
NVCR
NovoCure
0.00%+7.85%-4.61%+1.01%+5.08%
Westaim Corp. stock logo
WEDXF
Westaim
0.00%-0.88%-3.87%+2.92%+660.61%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CONMED Corporation stock logo
CNMD
CONMED
4.5713 of 5 stars
2.13.02.54.32.20.83.1
Enovis Corporation stock logo
ENOV
Enovis
3.2047 of 5 stars
3.43.00.00.01.81.71.9
NovoCure Limited stock logo
NVCR
NovoCure
3.7602 of 5 stars
3.31.00.04.53.11.70.0
Westaim Corp. stock logo
WEDXF
Westaim
0.267 of 5 stars
0.04.00.00.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CONMED Corporation stock logo
CNMD
CONMED
2.20
Hold$62.2019.59% Upside
Enovis Corporation stock logo
ENOV
Enovis
2.80
Moderate Buy$58.0082.51% Upside
NovoCure Limited stock logo
NVCR
NovoCure
2.67
Moderate Buy$32.8382.41% Upside
Westaim Corp. stock logo
WEDXF
Westaim
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest WEDXF, ENOV, NVCR, and CNMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
NovoCure Limited stock logo
NVCR
NovoCure
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$34.00
6/12/2025
CONMED Corporation stock logo
CNMD
CONMED
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$61.00
5/14/2025
Enovis Corporation stock logo
ENOV
Enovis
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$75.00 ➝ $70.00
5/9/2025
Enovis Corporation stock logo
ENOV
Enovis
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$62.00 ➝ $55.00
5/9/2025
Enovis Corporation stock logo
ENOV
Enovis
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$64.00 ➝ $57.00
5/1/2025
CONMED Corporation stock logo
CNMD
CONMED
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$70.00 ➝ $58.00
5/1/2025
CONMED Corporation stock logo
CNMD
CONMED
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$70.00 ➝ $57.00
5/1/2025
CONMED Corporation stock logo
CNMD
CONMED
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$91.00 ➝ $61.00
4/28/2025
CONMED Corporation stock logo
CNMD
CONMED
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$75.00 ➝ $55.00
4/23/2025
NovoCure Limited stock logo
NVCR
NovoCure
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.00
4/16/2025
NovoCure Limited stock logo
NVCR
NovoCure
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$29.00 ➝ $27.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CONMED Corporation stock logo
CNMD
CONMED
$1.31B1.23$6.69 per share7.77$31.16 per share1.67
Enovis Corporation stock logo
ENOV
Enovis
$2.11B0.86$19.26 per share1.65$45.10 per share0.70
NovoCure Limited stock logo
NVCR
NovoCure
$605.22M3.32N/AN/A$3.33 per share5.41
Westaim Corp. stock logo
WEDXF
Westaim
$17.04M44.49N/AN/A$23.28 per share0.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CONMED Corporation stock logo
CNMD
CONMED
$132.42M$3.8013.6910.261.349.02%14.36%5.86%7/30/2025 (Estimated)
Enovis Corporation stock logo
ENOV
Enovis
-$825.49M-$13.95N/A9.96N/A-37.65%5.99%3.44%8/6/2025 (Estimated)
NovoCure Limited stock logo
NVCR
NovoCure
-$168.63M-$1.51N/AN/AN/A-26.41%-45.46%-13.34%7/24/2025 (Estimated)
Westaim Corp. stock logo
WEDXF
Westaim
-$16.18M-$2.17N/AN/A-253.76%-9.36%-8.82%8/12/2025 (Estimated)

Latest WEDXF, ENOV, NVCR, and CNMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/24/2025Q2 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.40N/AN/AN/A$153.87 millionN/A
5/14/2025Q1 2025
Westaim Corp. stock logo
WEDXF
Westaim
-$0.0316-$0.34-$0.3084-$0.34$1.34 million($4.70) million
5/8/2025Q1 2025
Enovis Corporation stock logo
ENOV
Enovis
$0.74$0.81+$0.07-$0.98$558.80 million$558.83 million
4/30/2025Q1 2025
CONMED Corporation stock logo
CNMD
CONMED
$0.81$0.95+$0.14$0.19$313.38 million$321.26 million
4/24/2025Q1 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CONMED Corporation stock logo
CNMD
CONMED
$0.801.54%N/A21.05%N/A
Enovis Corporation stock logo
ENOV
Enovis
N/AN/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A
Westaim Corp. stock logo
WEDXF
Westaim
N/AN/AN/AN/AN/A

Latest WEDXF, ENOV, NVCR, and CNMD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/21/2025
CONMED Corporation stock logo
CNMD
CONMED
quarterly$0.201.34%6/13/20256/13/20257/3/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CONMED Corporation stock logo
CNMD
CONMED
0.91
2.26
1.00
Enovis Corporation stock logo
ENOV
Enovis
0.52
2.55
1.32
NovoCure Limited stock logo
NVCR
NovoCure
0.27
1.47
1.41
Westaim Corp. stock logo
WEDXF
Westaim
N/A
11.40
11.40

Institutional Ownership

CompanyInstitutional Ownership
CONMED Corporation stock logo
CNMD
CONMED
N/A
Enovis Corporation stock logo
ENOV
Enovis
98.45%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%
Westaim Corp. stock logo
WEDXF
Westaim
N/A

Insider Ownership

CompanyInsider Ownership
CONMED Corporation stock logo
CNMD
CONMED
3.10%
Enovis Corporation stock logo
ENOV
Enovis
2.70%
NovoCure Limited stock logo
NVCR
NovoCure
5.52%
Westaim Corp. stock logo
WEDXF
Westaim
4.21%
CompanyEmployeesShares OutstandingFree FloatOptionable
CONMED Corporation stock logo
CNMD
CONMED
3,90030.94 million29.98 millionOptionable
Enovis Corporation stock logo
ENOV
Enovis
7,36757.12 million55.58 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,488111.49 million105.33 millionOptionable
Westaim Corp. stock logo
WEDXF
Westaim
733.56 million32.14 millionNot Optionable

Recent News About These Companies

Head to Head Survey: Hawkins (NASDAQ:HWKN) vs. Westaim (OTCMKTS:WEDXF)
The Westaim Corporation Reports Q1 2025 Results
Westaim completes acquisition of ManhattanLife
The Westaim Corp WEDXD
Westaim: Stocks Undervalued by Analyst Consensus on TSX-V (WED)
The Westaim Corporation appoints CRO
Westaim Corporation: A Bargain In The Asset Management World
Westaim Corporation: Still Undervalued Based On NAV
The Westaim Corporation (WEDXF)

New MarketBeat Followers Over Time

Media Sentiment Over Time

CONMED stock logo

CONMED NYSE:CNMD

$52.01 -0.33 (-0.63%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$52.14 +0.13 (+0.25%)
As of 06/27/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

Enovis stock logo

Enovis NYSE:ENOV

$31.78 -0.48 (-1.49%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$31.76 -0.01 (-0.04%)
As of 06/27/2025 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

NovoCure stock logo

NovoCure NASDAQ:NVCR

$18.00 +0.90 (+5.26%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$17.99 -0.01 (-0.06%)
As of 06/27/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Westaim stock logo

Westaim OTCMKTS:WEDXF

$22.59 +0.04 (+0.18%)
As of 06/27/2025 02:35 PM Eastern

The Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada.